Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
CA 2415923 C · Owner: Jakobovits, Aya · Inventors: Challita-Eid, Pia M.; Hubert, Rene S.; Faris, Mary
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compositions for the diagnosis and therapy of bladder lung, ovary, and kidney , cancer, derived from or based on a normally prostate-specific androgen-, regulated, cell membrane associated an secreted serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (Figure 1). Among the compositions provided are antibodies that bind to 20P1F12/MPRSS2 proteins and polypeptide fragments thereof including , antibodies labeled with a detectable marker or toxin or therapeutic composition. The invention also provides prognostic and diagnostic methods of examining a …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 12, 2001 and granted October 25, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 12, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 12, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.